Literature DB >> 25716146

Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem.

Binfeng Xia1, Zhen Yang, Haiying Zhou, Viera Lukacova, Wei Zhu, Mikolaj Milewski, Filippos Kesisoglou.   

Abstract

Intraoral (IO) delivery is an alternative administration route to deliver a drug substance via the mouth that provides several advantages over conventional oral dosage forms. The purpose of this work was to develop and evaluate a novel, physiologically based oral cavity model for projection and mechanistic analysis of the clinical pharmacokinetics of intraoral formulations. The GastroPlus™ Oral Cavity Compartmental Absorption and Transit (OCCAT™) model was used to simulate the plasma concentration versus time profiles and the fraction and rate of intraoral drug transit/absorption for Intermezzo® sublingual tablets (zolpidem tartrate). The model was evaluated by the goodness-of-fit between simulated and observed concentrations and the deviation of key PK parameters (e.g., C max, T max, and AUC). In addition, a sensitivity analysis was conducted to demonstrate the interplay and impact of key modeling parameters on the fraction absorbed via oral mucosa (F a_IO). The OCCAT™ model captured the observed pharmacokinetics for Intermezzo® sublingual tablets (R (2) > 0.9). The predicted deviations (%) for C max, AUC0-inf, AUC0-20 min, and T max were 5.7, 28.0, 11.8, and 28.6%, respectively, indicating good prediction accuracy. The model also estimated ~18% of total drug was absorbed via the IO route. Furthermore, the sensitivity analysis indicated that the F a_IO was not only associated with drug diffusivity and unbound fraction in epithelium tissue (f ut) but also depended on the physicochemical properties of compounds for IO delivery (e.g., solubility and logD pH = 7.4). The novel physiologically based IO absorption OCCAT™ model showed satisfactory performance and will be helpful to guide development of future intraoral formulations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25716146      PMCID: PMC4406949          DOI: 10.1208/s12248-015-9727-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  36 in total

1.  Thickness of masticatory mucosa.

Authors:  H P Müller; N Schaller; T Eger; A Heinecke
Journal:  J Clin Periodontol       Date:  2000-06       Impact factor: 8.728

Review 2.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Authors:  B Agoram; W S Woltosz; M B Bolger
Journal:  Adv Drug Deliv Rev       Date:  2001-10-01       Impact factor: 15.470

3.  Measurement of epithelial thickness within the oral cavity using optical coherence tomography.

Authors:  Sven Prestin; Sacha I Rothschild; Christian Stephan Betz; Marcel Kraft
Journal:  Head Neck       Date:  2012-02-09       Impact factor: 3.147

4.  Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels.

Authors:  Harish Shankaran; Femi Adeshina; Justin G Teeguarden
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-31       Impact factor: 4.219

Review 5.  PBPK models for the prediction of in vivo performance of oral dosage forms.

Authors:  Edmund S Kostewicz; Leon Aarons; Martin Bergstrand; Michael B Bolger; Aleksandra Galetin; Oliver Hatley; Masoud Jamei; Richard Lloyd; Xavier Pepin; Amin Rostami-Hodjegan; Erik Sjögren; Christer Tannergren; David B Turner; Christian Wagner; Werner Weitschies; Jennifer Dressman
Journal:  Eur J Pharm Sci       Date:  2013-09-21       Impact factor: 4.384

6.  Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.

Authors:  Jeremy A Bartlett; Kees van der Voort Maarschalk
Journal:  AAPS PharmSciTech       Date:  2012-08-31       Impact factor: 3.246

7.  Correlation of partition coefficients in n-heptane-aqueous systems with buccal absorption data for a series of amines and acids.

Authors:  A H Beckett; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1969-12       Impact factor: 3.765

Review 8.  New developments and opportunities in oral mucosal drug delivery for local and systemic disease.

Authors:  Vanessa Hearnden; Vidya Sankar; Katrusha Hull; Danica Vidović Juras; Martin Greenberg; A Ross Kerr; Peter B Lockhart; Lauren L Patton; Stephen Porter; Martin H Thornhill
Journal:  Adv Drug Deliv Rev       Date:  2011-03-01       Impact factor: 15.470

9.  Architecture and density of the connective tissue papillae of the human oral mucosa.

Authors:  A J Klein-Szanto; H E Schroeder
Journal:  J Anat       Date:  1977-02       Impact factor: 2.610

10.  Absorption kinetics of sublingually administered propranolol.

Authors:  R E Kates
Journal:  J Med       Date:  1977
View more
  5 in total

1.  Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans.

Authors:  Li Zhou; Peipei Zhang; Zhuo Chen; Shaona Cai; Ting Jing; Huihui Fan; Fei Mo; Jiye Zhang; Rong Lin
Journal:  Int J Nanomedicine       Date:  2017-06-06

2.  Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym.

Authors:  Diane M Longo; Lisl K M Shoda; Brett A Howell; Vladimir Coric; Robert M Berman; Irfan A Qureshi
Journal:  Toxicol Sci       Date:  2020-06-01       Impact factor: 4.849

3.  Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film.

Authors:  Fang Chen; Hongrui Liu; Bing Wang; Liuliu Yang; Weimin Cai; Zheng Jiao; Zhou Yang; Yusheng Chen; Yingjun Quan; Xiaoqiang Xiang; Hao Wang
Journal:  Front Pharmacol       Date:  2020-02-03       Impact factor: 5.810

4.  3D Printed Buccal Films for Prolonged-Release of Propranolol Hydrochloride: Development, Characterization and Bioavailability Prediction.

Authors:  Marija Jovanović; Miloš Petrović; Sandra Cvijić; Nataša Tomić; Dušica Stojanović; Svetlana Ibrić; Petar Uskoković
Journal:  Pharmaceutics       Date:  2021-12-13       Impact factor: 6.321

5.  Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study.

Authors:  Maxime Le Merdy; Jim Mullin; Viera Lukacova
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-26       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.